Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Exploiting New Patterns of Genome Damage in Triple Negative Breast Cancer

ABSTRACT: Exploiting New Patterns of Genome Damage in Triple Negative Breast Cancer

PROVIDER: PRJNA871342 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Exploiting New Patterns of Genome Damage in Triple Negative Breast Cancer

Project description:Exploiting New Patterns of Genome Damage in Triple Negative Breast Cancer

| PRJNA871343 | ENA

Damage-associated molecular patterns by dying cancer cells

Project description:The molecular hallmark of immunogenic cell death (ICD) features the release of damage-associated molecular patterns (DAMPs) by dying cancer cells. Herein, measuring DAMPs from gemcitabine-induced dying cancer cells, via mass spectrometry (MS) proteomic profiling.

2020-11-04 | MSV000086407 | MassIVE

MLK4 kinase regulates the DNA damage response and promotes triple-negative breast cancer chemoresistance

Project description:Triple-negative breast cancer (TNBC) is a subtype of breast cancer characterized by the absence of estrogen and progesterone receptors, and the lack of HER2 amplification or overexpression. Chemoresistance is currently one of the major challenges in the treatment TNBC. Therefore, there is a need towards identification of the novel molecular targets that could be exploited to overcome TNBC chemoresistance. In this study, we found that knock-down of Mixed-Lineage Kinase 4 (MLK4), a member of MAP3K family of serine/threonine kinases, sensitizes TNBC cell to chemotherapy and impairs activation of DNA repair pathways upon genotoxic treatment. DNA damage response signaling network coordinates transcriptional response at multiple levels to preserve cellular homeostasis and promote survival in response to genotoxic stress. Since MLK4-deficient cells were compromised for DNA damage response signaling activation following doxorubicin treatment, we hypothesized that the loss of MLK4 could significantly affect global transcriptomic changes induced by chemotherapy in TNBC cells. To test this hypothesis we performed gene expression profiling by mRNA-seq in HCC1806 TNBC cells transfected with control or MLK4-targeting siRNAs and treated with either 1 μM of doxorubicin for 24 h or vehicle only (DMSO control). Our RNA-seq analysis revealed that MLK4 is required for DNA damage-induced expression of several NF-кB-associated cytokines, including IL-6, which facilitates TNBC cells survival in an autocrine manner.

2021-11-28 | GSE174692 | GEO

Damage-associated molecular patterns (DAMPs) by dying cancer cells

2020-10-29 | MSV000086386 | MassIVE

MLK4 kinase regulates the DNA damage response and promotes triple-negative breast cancer chemoresistance

Project description:MLK4 kinase regulates the DNA damage response and promotes triple-negative breast cancer chemoresistance

| PRJNA731126 | ENA

Triple therapy reduced metastasis in triple-negative breast cancer

Project description:Triple therapy reduced metastasis in triple-negative breast cancer

| PRJNA857888 | ENA

Triple therapy reduced metastasis in triple-negative breast cancer.

Project description:Triple therapy reduced metastasis in triple-negative breast cancer.

| PRJNA832953 | ENA

Transient splicing inhibition causes persistent DNA damage and enhances chemotherapy vulnerability in homologous recombination proficient triple-negative breast cancer

Project description:Triple negative breast cancer (TNBC) is an aggressive subtype of breast cancer. Most TNBCs are initially sensitive to DNA damaging chemotherapy, a substantial fraction acquire resistance to treatments and progress to advanced stages associated with poor prognosis. We identify the spliceosome U2 small nuclear ribonucleoprotein (snRNP) complex as a modulator of chemotherapy efficacy in TNBC. Transient treatment with U2snRNP inhibitors induced a persistent DNA damage in TNBC cells and patient-derived organoids (PDOs), regardless of their homologous recombination proficiency. Transcriptome analyses revealed that U2snRNP inhibition causes a pervasive deregulation of genes involved in the DNA damage response (DDR), which relied on their genomic structure characterized by a high number of small exons. Importantly, a pulse of splicing inhibition was sufficient to elicit long-lasting repression of DDR proteins and to enhance the cytotoxic effect of platinum-based drugs and poly ADP-ribose polymerase inhibitors (PARPi) in multiple TNBC models. These findings identify the U2snRNP as an actionable target that can be exploited to enhance chemotherapy efficacy in TNBCs.

2025-07-04 | GSE271749 | GEO

Triple Negative Breast Cancer RNA Sequencing

Project description:We propose to definitively characterise the somatic genetics of triple negative breast cancer through generation of comprehensive catalogues of somatic mutations in breast cancer cases by high coverage genome sequencing coupled with integrated transcriptomic and methylation analyses.

2015-04-16 | E-ERAD-113 | biostudies-arrayexpress

Triple Negative Breast tumors: SPARC Positive Tumors vs SPARC Negative Tumors

Project description:The aim of this study was evaluate the transcriptome changes in the comparison between triple negative tumors with increased SPARC expression and triple negative tumors with decreased SPARC expression according to Nagai et al., 2011 (Breast Cancer Res Treat (2011) 126:1–14) The results generated could be of particular interest to better define the prognostic impact of SPARC expression in triple negative breast tumors

2018-07-01 | GSE98931 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data